Concepedia

Author

Makoto Maemondo

Miyagi Prefectural Hospital OrganizationORCID

Also Known As

M Maemondo, M. Maemondo, Makoto Maemondo, Masahiro Kobayashi, Shunichi Sugawara, Toyoaki Hida

303

Publications

15.6K

Citations

46

H-Index

87

Concepts

All Affiliations

Miyagi Prefectural Hospital OrganizationTohoku UniversityIwate Medical UniversitySendai Kousei HospitalTohoku University Hospital
MM

About

Makoto Maemondo is an author at Miyagi Prefectural Hospital Organization specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

31

56

5.2K

2

Cell Biology

10

11

754

3

Health Sciences

7

7

166

4

Public Health

1

1

33

5

Cellular Therapies

1

1

154

Makoto Maemondo

×

108

Publications

14.3K

Citations

44

H-Index

YearCitations

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi,

New England Journal of Medicine

2010

5.5K

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya,

The Lancet Oncology

2019

626

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

Takashi Seto, Katsuyuki Kiura, Makoto Nishio,

The Lancet Oncology

2013

576

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim,

The Lancet Oncology

2018

568

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

Akira Inoue, Kunihiko Kobayashi, Makoto Maemondo,

Annals of Oncology

2012

549

First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy

Akira Inoue, Kunihiko Kobayashi, Kazuhiro Usui,

Journal of Clinical Oncology

2009

515

Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

Akira Inoue, Takuji Suzuki, Tatsuro Fukuhara,

Journal of Clinical Oncology

2006

503

Severe acute interstitial pneumonia and gefitinib

Akira Inoue, Yasuo Saijo, Makoto Maemondo,

The Lancet

2003

452

Proinflammatory Cytokine IL-1β Promotes Tumor Growth of Lewis Lung Carcinoma by Induction of Angiogenic Factors: In Vivo Analysis of Tumor-Stromal Interaction

Yasuo Saijo, Masashi Tanaka, Makoto Miki,

The Journal of Immunology

2002

247

Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402

Akira Inoue, Shunichi Sugawara, Koichi Yamazaki,

Journal of Clinical Oncology

2008

233

Page 1